Five Under 5: Top Oncology Videos for the Week of 3/2

Welcome to The Five Under 5, your go-to roundup of the top 5 videos of the week.

These short videos are designed for busy oncologists to view on the go, and feature expert insights on breaking news, regulatory updates, practice-changing data shared at medical meetings, and other key topics in the realm of oncology.

Here’s what you may have missed:

William D. Tap, MD, of, Memorial Sloan Kettering Cancer Center, discusses the significance of the FDA approval of vimseltinib (Romvimza) for patients with symptomatic tenosynovial giant cell tumor (TGCT), particularly those for whom surgery may cause worsening functional limitations or severe morbidity. He highlights that the decision is based on findings from the phase 3 MOTION trial (NCT05059262), where the agent showed a 40% response rate, offering a promising non-surgical treatment alternative. Tap emphasizes that vimseltinib’s approval, alongside pexidartinib (Turalio), provides a second systemic therapy option, enhancing the ability to tailor treatments to individual patients.

Caicun Zhou, MD, PhD, of Shanghai Pulmonary Hospital, spotlights data from the phase 3 HARMONi-2 trial (NCT05499390), which compared ivonescimab (AK112) with pembrolizumab (Keytruda) as first-line treatment for patients with PD-L1–positive advanced non–small cell lung cancer (NSCLC). Ivonescimab significantly improved progression-free survival (PFS), with a median PFS of 11.14 months vs 5.82 months for pembrolizumab; the agent also led to higher overall response and disease control rates. Zhou also notes that ivonescimab had a manageable safety profile with no new toxicity concerns reported, supporting its potential as a first-line treatment option for advanced NSCLC.

Angela Jain, MD, from Fox Chase Cancer Center, discusses challenges in the treatment of patients with triple-negative breast cancer (TNBC), highlighting the aggressiveness of the disease and the need for optimal treatment strategies. Although novel treatments such as neoadjuvant camrelizumab combined with chemotherapy show promise in improving pathologic complete response (pCR) rates, there remains an unmet need for effective patient-specific options. Jain also notes the emerging importance of biomarkers and the shift in the landscape with HER2-low disease, which could open the door for targeted therapies like fam-trastuzumab deruxtecan-nxki (Enhertu).

Jin-Ji Yang, MD, of Guangdong Lung Cancer Institute, Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, discusses findings from the phase 2 FLOWERS trial (NCT05163249) evaluating osimertinib (Tagrisso) in combination with savolitinib as a first-line treatment for de novo MET-aberrant, EGFR-mutant advanced NSCLC. The combination therapy showed a significantly higher objective response rate (90.5%) and disease control rate (95.2%) vs osimertinib monotherapy, with promising but immature progression-free survival data suggesting a potential clinical benefit. The combination regimen also had a manageable safety profile, although higher rates of grade 3 or higher treatment-emergent adverse effects were observed with the regimen vs osimertinib alone. No treatment-related deaths occurred.

Yasmin Abaza, MD, of Robert H. Lurie Comprehensive Cancer Center of Northwestern University, discusses the unmet needs for targeted therapies in acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS), particularly for those with splicing factor mutations. She highlights the ongoing evaluation of the investigational agent emavusertib (CA-4948) in the phase 1/2 TakeAim Leukemia trial (NCT04278768), which aims to address the need for new targeted options. Although early data on emavusertib and other kinase inhibitors show promise, larger studies are needed to establish their efficacy and clinical benefit for patients with high-risk AML and MDS.